Palatin Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of receptor-specific peptide therapeutics to address a range of human health conditions. Founded in 1996 and headquartered in Davie, Florida, the company has built a technology platform centered on melanocortin receptors, which play key roles in regulating sexual function, inflammation, cardiovascular health and metabolic processes. Palatin’s research efforts aim to create targeted treatments with improved safety profiles compared with existing therapies.
The company’s lead product candidate, bremelanotide (Vyleesi®), is a melanocortin receptor agonist designed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide received approval from the U.S. Food and Drug Administration in 2019 and is commercialized in the United States through a partnership with AMAG Pharmaceuticals, which handles marketing, sales and distribution. In addition to its female sexual health program, Palatin is advancing earlier-stage assets directed at conditions such as heart failure and inflammatory disorders, leveraging its expertise in peptide chemistry and receptor biology.
Palatin Technologies conducts its research and development primarily in North America, while its commercialization and partnership strategy extends into Europe and other key global markets. The company has collaborated with multiple pharmaceutical partners to secure development and commercial rights for its products outside the United States, enabling it to tap into regulated markets with established distribution networks and regulatory expertise. Clinical trials have been conducted across the U.S. and Europe to support regulatory filings and to broaden the potential patient base for its therapies.
Under the leadership of President and Chief Executive Officer Mark J. Struthers, Palatin maintains a lean organizational structure that combines in-house scientific, clinical and regulatory capabilities with external expertise for manufacturing and commercialization. The company’s management team and board of directors include executives with decades of experience in biopharmaceutical research, clinical development and product launch, positioning Palatin to advance its pipeline toward potential regulatory approvals and commercial readiness.
AI Generated. May Contain Errors.
Free PTN Stock Alerts